TScan Therapeutics, Inc.
Formerly T-Scan Therapeutics, Inc.
TScan Therapeutics, Inc. is listed today as TScan Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2021 | $100 M | No. 2 | $50 to $250 million | equity | SEC | |
| Jul 2019 | $23 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company TScan Therapeutics, Inc., its revenue in fiscal 2025 came from these business segments: Reportable $10.32 million (100%).
Annual report (SEC XBRL) · Dec 2025
TScan Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2021).
SEC Form D · Jan 2021
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jan 2021
Products and services#
No products or services of TScan Therapeutics, Inc. are on record.
Investors#
5 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| 667, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| Baker Bros. Advisors (GP) LLC | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| Baker Bros. Advisors LP | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| Baker Brothers Life Sciences LP | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| Timothy J. Barberich | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 16 investors.
Largest shareholders today
Institutions holding TScan Therapeutics, Inc. shares, as of Sep 30, 2026.
- Lynx1 Capital Management LP$3 M11.83%
- BVF Inc/il$2 M8.21%
- Boothbay Fund Management, LLC$1 M5.01%
- Baker Bros. Advisors LP$1 M4.11%
- Vanguard Capital Management LLC$1 M3.70%
- Acadian Asset Management LLC$1 M2.50%
- Two Sigma Investments, LP$1 M2.43%
- Deer Management Co. LLC$0 M1.84%
- Renaissance Technologies LLC$0 M1.78%
- DC Funds, LP$0 M0.93%
- Geode Capital Management, LLC$0 M0.89%
- BlackRock, Inc.$0 M0.88%
- Gsa Capital Partners LLP$0 M0.75%
- Vanguard Fiduciary Trust Co$0 M0.54%
- Marshall Wace, LLP$0 M0.40%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David Southwell | Executive officer | Jan 2021 |
| Robert Crane | Executive officer | Jul 2019 |
| Andrew Hedin | Director | Jan 2021 |
| Brian Silver | Director | Jan 2021 |
| Christoph Westphal | Director | Jan 2021 |
| David Southwell | Director | Jan 2021 |
| Doug Fambrough | Director | Jan 2021 |
| Ittai Harel | Director | Jan 2021 |
| Nandita Shangari | Director | Jan 2021 |
| Timothy Barberich | Director | Jan 2021 |
| Campbell Murray | Director | Jul 2019 |
| Hannes Smarason | Director | Jul 2019 |
| Lea Hachigian | Director | Jul 2019 |
| Steve Kraus | Director | Jul 2019 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.